Meningitis in diabetic patients.
Community acquired bacterial (CBM) meningitis in diabetic patients was analyzed for risk factors and outcome in a cohort of 201 cases of meningitis within last 17 years: 15 patients with diabetes mellitus and meningitis were identified and compared for etiology and mortality as well as for neurologic sequellae with all CBM cases.
Muli
J M
JM
St. Elizabeth University College.
Seckova
S
S
Sladeckova
V
V
Steno
J
J
Adamcova
J
J
Rabarova
L
L
Takacova
M
M
Polonova
J
J
Dudasova
T
T
Pauerova
K
K
Namulanda
V
V
Okoth
V
V
Juma
O
O
Diana
E
E
Johnson
M J
MJ
Deadline
J
J
Bartkovjak
M
M
Kolenova
A
A
Taziarova
M
M
Benca
J
J
Njambi
Z
Z
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002439:Cefotaxime / Q000627:therapeutic use; D015331:Cohort Studies; D017714:Community-Acquired Infections / Q000382:microbiology / Q000401:mortality / Q000628:therapy; D048909:Diabetes Complications / Q000276:immunology / Q000382:microbiology* / Q000628:therapy; D003920:Diabetes Mellitus / Q000276:immunology*; D006801:Humans; D016920:Meningitis, Bacterial / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D017063:Outcome Assessment, Health Care; D012307:Risk Factors; D014640:Vancomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin; D002439:Cefotaxime